Arcagy/ Gineco Group

This phase 2 study tests whether adding relatlimab to the standard immunotherapy nivolumab can shrink tumors in people with locally advanced cervical cancer. About 77 participants will receive either the drug combination or nivolumab alone for 6 weeks. The main goal is to see how…

This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy for people with a specific type of advanced or recurrent endometrial cancer (MMR deficient). About 260 participants will be randomly assigned to receive either dostarlimab or chemo…